Skip to ContentSkip to Navigation
How to find us F. Bensch


Assessment of Bone Lesions with F-18-FDG PET Compared with Tc-99m Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management

Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results

Interobserver reproducibility of tumor uptake quantification with Zr-89-immuno-PET: a multicenter analysis

Molecular imaging on the move: From feasibility to contribution in clinical questions

Comparative biodistribution analysis across four different Zr-monoclonal antibody tracers-The first step towards an imaging warehouse

Molecular imaging to enlighten cancer immunotherapies and underlying involved processes

Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

Clinical value of Zr-89-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma

First-in-human PET imaging with the PD-L1 antibody Zr-89-atezolizumab

Read more